论文部分内容阅读
目的探讨前程加卡铂后程野中野加速超分割放射治疗食管癌的疗效。材料与方法自１９９１年１０月至１９９３年６月对９０例食管癌病人随机分常规放射治疗组（常规组）和前程加卡铂后程野中野加速超分割放疗组（前化后超组）各４５例。两组临床资料相近，具备可比性。常规组每周照５次，每次２Ｇｙ，总量６０～７０Ｇｙ；前化后超组前３周放疗同常规组，配合卡铂每周两次，每次１００ｍｇ，总量６００ｍｇ。第４，５周在原照射野中设小野（同病变长度），每次１．５Ｇｙ，每周５次，上午照大野，下午照小野，总量５周６５Ｇｙ，其中大野５周５０Ｇｙ，小野后两周１５Ｇｙ。结果放疗结束时Ｘ线改善前化后超组病灶全消和消失１／２以上８６．７％（３９／４５），常规组５７．８％（２６／４５）（Ｐ＜０．０１）。１，２，３，４年生存率分别为７５．６％、５３．３％、４２．２％、３３．３％和５５．６％、３１．１％、２０．０％、１５．６％。前化后超组明显好于常规组（Ｐ＜０．０５）。结论前程配合卡铂后程大野套小野加速超分割放射治疗能显著提高食管癌１，２，３，４年生存率，病人能顺利完成疗程。
Objective To investigate the curative effect of the prospective plus carboplatin late-field Nakano accelerated hyperfractionated radiotherapy for esophageal cancer. Materials and Methods From October 1991 to June 1993, 90 patients with esophageal cancer were randomly divided into conventional radiotherapy group (conventional group) and preoperative plus carboplatin late course Nakano accelerated hyperfractionated radiotherapy group (pre-postoperative hypergroup). 45 cases. The two groups of clinical data are similar and comparable. The routine group received 5 times a week for 2Gy each time, and the total amount was 60-70Gy. The preoperative group received radiotherapy for the first 3 weeks and the same group as the conventional group. Carboplatin was administered twice a week for 100mg and the total amount was 600mg. In the 4th and 5th weeks, the Ono field was set up with Ono (with lesion length) 1.5Gy each time, 5 times a week, morning according to Ohno, afternoon according to Ono, total 5 weeks 65Gy, including Ohno 5 weeks 50Gy, Ono two Week 15Gy. RESULTS: After the end of radiotherapy, the X-rays improved and the lesions in the super group disappeared and disappeared by more than 1/2, 86.7% (39/45), and in the conventional group, 57.8% (26/45) (P<0.01). The 1, 2, 3, and 4 year survival rates were 75.6%, 53.3%, 42.2%, 33.3%, and 55.6%, 31.1%, 20.0%, and 15.6, respectively. %. After the pretreatment, the super group was significantly better than the conventional group (P<0.05). Conclusion Accelerated hyperfractionated radiation therapy combined with the prospective combination of carboplatin and Houyeyeyeyeye significantly improved the 1, 2, 3, and 4 years survival rate of esophageal cancer, and the patient could successfully complete the course of treatment.